CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

Stock Information for Cytodyn Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytodyn Inc

December 2025 Letter to Shareholders
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
CytoDyn Announces Resolution of Class Action Lawsuit
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
CytoDyn Secures $30 Million Commitment from Yorkville Advisors
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
September 2025 Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.